Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the development of the pipeline candidate, birtamimab. The decision to discontinue ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard ...

Novo Nordisk is trading at a slight premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 15.78 forward earnings ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively. In recent years, these pharma giants have become even ...